Publications by authors named "Chuang-Zhou Rao"
Genes Chromosomes Cancer
April 2022
Article Synopsis
- Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) shows strong responses to ALK tyrosine kinase inhibitors (TKIs), particularly in cases involving EML4-ALK fusions, but there is limited research on HIP1-ALK fusions.
- A study of 11 patients with HIP1-ALK fusions in Chinese centers reported a high response rate of 90% for crizotinib treatment, with promising survival outcomes although the sample size was small.
- Resistance to ALK-TKIs in these patients is linked to genetic mutations and fusions, indicating the need for larger studies to better understand treatment efficacy and resistance mechanisms in HIP1-ALK-rearranged NSCLC.
Transl Lung Cancer Res
October 2020
Article Synopsis
- Chemotherapy, particularly pemetrexed-based regimens, is the primary treatment for advanced non-small-cell lung cancer (NSCLC) patients with specific genetic mutations called EGFR exon 20 insertions (ex20ins), although the research is limited on different subtypes.
- A study analyzed data from 119 patients with EGFR ex20ins, revealing that those treated with pemetrexed had a longer progression-free survival and showed a tendency for better overall survival compared to those who were not treated with it.
- The research suggests that the specific subtype of EGFR ex20ins may influence survival outcomes, with certain subtypes showing a potential advantage, while factors like histological type and bone metastasis are important for prognosis.
